Loan & DebtAug 3, 2026, 07:16 AM
Autolus Secures $250M Credit Facility; Raises FY26 Revenue Guidance
AI Summary
Autolus Therapeutics announced preliminary second quarter 2026 AUCATZYL net product revenue of approximately $45 million and a gross margin of about 35% year-to-date. The company raised its full-year 2026 sales guidance to $140 – $150 million, up from $120 – $135 million. Additionally, Autolus secured a five-year, interest-only senior credit facility of up to $250 million with Perceptive Advisors, with an initial $75 million funded at close, strengthening its capital base and extending its funding runway into Q2 2028.
Key Highlights
- Secured a five-year, interest-only senior credit facility of up to $250 million with Perceptive Advisors.
- Initial $75 million principal amount funded at close, with an additional $25 million available at Autolus' option.
- Preliminary Q2 2026 AUCATZYL net product revenue reached approximately $45 million.
- Year-to-date FY 2026 sales guidance increased to $140 – $150 million, up from $120 – $135 million.
- Gross margin improved to approximately 35% year-to-date FY 2026, from negative 20% in H2 2025.
- AUCATZYL sales increased approximately 70% over Q1 2026 and over 100% compared to Q2 2025.
- Issued a warrant to Perceptive to purchase up to 3.5 million ADSs at an exercise price of $1.9314 per ADS.
- Combined first and second tranches ($100 million) provide funding into Q2 2028.
Price Impact
More from AUTL